ReviewCureus2026
Peri-Coronary Adipose Tissue Attenuation and Atrial Fibrillation Recurrence After Catheter Ablation: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCatheter ablation is an established rhythm-control strategy for atrial fibrillation (AF), but arrhythmia recurrence after the procedure remains a major clinical challenge. Reliable pre-procedural biomarkers reflecting the underlying inflammatory substrate may improve risk stratification and patient selection. Peri-coronary adipose tissue (PCAT) attenuation, measured on coronary computed tomography angiography (CCTA), is a noninvasive imaging marker of coronary perivascular inflammation. This study evaluated the association between PCAT attenuation and AF recurrence after catheter ablation.
methodsWe systematically searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials through October 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, for studies comparing PCAT attenuation between patients with and without AF recurrence after catheter ablation. Pooled mean differences (MDs) with 95% confidence intervals (CIs) were calculated separately for each coronary territory using random-effects models with restricted maximum likelihood estimation of the between-study variance and Knapp-Hartung-Sidik-Jonkman-corrected confidence intervals, an approach recommended when the number of available studies is small. DerSimonian-Laird estimates with Wald intervals are reported alongside for comparison. Standardized MDs were calculated in parallel. Heterogeneity was assessed using the I² statistic, and leave-one-out analysis was performed as a descriptive check.
resultsThree retrospective cohort studies enrolling 852 patients (239, 28%, with AF recurrence) met the inclusion criteria. PCAT attenuation was numerically higher in patients with AF recurrence across all three major coronary territories, but under the small-sample-corrected model, none of the associations reached statistical significance: right coronary artery (RCA)-PCAT (MD 2.62 HU; 95% CI -2.41 to 7.65), left anterior descending artery (LAD)-PCAT (MD 1.53 HU; 95% CI -1.45 to 4.50), and left circumflex artery (LCx)-PCAT (MD 2.48 HU; 95% CI -0.70 to 5.66). Corresponding standardized MDs were 0.30, 0.23, and 0.36. Conventional DerSimonian-Laird estimates with Wald intervals were nominally significant in all three territories despite identical point estimates, reflecting the degree to which precision is overstated when the between-study variance is estimated from three studies. Because each patient contributed correlated measurements across territories, no overall pooled estimate combining territories was calculated. Heterogeneity was moderate (I² 34-65%) but imprecisely estimated.
conclusionPre-ablation PCAT attenuation was consistently higher in patients who subsequently experienced AF recurrence after catheter ablation, but the pooled differences of approximately 1.5-2.6 HU did not reach statistical significance once appropriate small-sample corrections were applied and are of a magnitude comparable to reported technical variability in PCAT measurement across CT acquisition protocols. The consistent direction of effect across three independent cohorts is of interest and supports further investigation, but these data do not establish PCAT attenuation as a predictor of post-ablation recurrence and provide no basis for clinical application. Prospective multicenter studies with standardized acquisition and segmentation protocols are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.